Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Baalbergen, Astrid ^a   Veenstra, Yerney ^a   Stalpers, Lukas ^b  

^a REINIER DE GRAAF HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT RADIOTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; EARLY CANCER; HUMAN; INTERMETHOD COMPARISON; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SAFETY; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SURVIVAL TIME; SYSTEMATIC REVIEW; UTERINE CERVIX ADENOCARCINOMA; ADENOCARCINOMA; ADJUVANT THERAPY; FEMALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

MLCS; MLOWN;

EID: 84874806840     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006248.pub3     Document Type: Review

References (94)

1. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535-40.
2. Angel C, DuBeshter B, Lin JY. Clinical presentation and management of stage I cervical adenocarcinoma: a 25 year experience. Gynecologic Oncology 1992;44(1):71-8.
3. Attanoos R, Nahar K, Bigrigg A, Roberts S, Newcombe RG, Ismail SM. Primary adenocarcinoma of the cervix. A clinicopathologic study of prognostic variables in 55 cases. International Journal of Gynecological Cancer 1995;5:179-86.
4. Baalbergen A, Ewing-Graham PC, Hop WC, Struijk P, Helmerhorst TJ. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecologic Oncology 2004;92(1):262-7.
5. Bansal N, Herzog TJ, Shaw RE, Burke WM, Deutsch I, Wright JD. Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. American Journal of Obstetrics and Gynecology 2009;201(5):485 e1-9.
6. Berek JS, Castaldo TW, Hacker NF, Petrilli ES, Lagasse LD, Moore JG. Adenocarcinoma of the uterine cervix. Cancer 1981;48(12):2734-41.
7. Chargui R, Damak T, Khomsi F, Ben Hassouna J, Chaieb W, Hechiche M, et al. Prognostic factors and clinicopathologic characteristics of invasive adenocarcinoma of the uterine cervix. American Journal of Obstetrics and Gynecology 2006;194(1):43-8.
8. Charkviani L, Charkviani T, Natenadze N. The management of cervical cancer in the experience of oncological institute of Tbilisi. European Journal of Gynaecological Oncology 1990;11(4):257-62.
9. Chen RJ, Chang DY, Yen ML, Lee EF, Huang SC, Chow SN, et al. Prognostic factors of primary adenocarcinoma of the uterine cervix. Gynecologic Oncology 1998;69(2):157-64.
10. Covens A, Kirby J, Shaw P, Chapman W, Franseen E. Prognostic factors for relapse and pelvic lymph node metastases in early stage I adenocarcinoma of the cervix. Gynecologic Oncology 1999;74(3):423-7.
11. Eifel PJ, Morris M, Oswald MJ, Wharton JT, Delclos L. Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer 1990;65(11):2507-14.
12. Eifel PJ, Burke TW, Delclos L, Wharton JT, Oswald MJ. Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors less than or equal to 4 cm in diameter. Gynecologic Oncology 1991;41(3):199-205.
13. Erzen M, Mozina A, Bertole J, Syrjanen K. Factors predicting disease outcome in early stage adenocarcinoma of the uterine cervix. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2002;101(2):185-91.
14. Farley JH, Hickey KW, Carlson JW, Rose GS, Kost ER, Harrison TA. Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma. Cancer 2003;97(9):2196-202.
15. Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS, Hershman DL, Wright JD. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecologic Oncology 2012;125(2):278-91.
16. Grigsby PW, Perez CA, Kuske RR, Camel HM, Kao MS, Galakatos AE, et al. Adenocarcinoma of the uterine cervix: lack of evidence for a poor prognosis. Radiotherapy and Oncology 1988;12(4):289-96.
17. Hansen MK. Surgical and combination therapy of cancer of the cervix uteri stages Ib and IIa. Gynecologic Oncology 1981;11(3):275-87.
18. Hopkins MP, Schmidt RW, Roberts JA, Morley GW. The prognosis and treatment of stage I adenocarcinoma of the cervix. Obstetrics and Gynecology 1988;72:915-21.
19. Hopkins MP, Morley GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstetrics and Gynecology 1991;77(6):912-7.
20. Hurt WG, Silverberg SG, Frable WJ, Belgrad R, Crooks LD. Adenocarcinoma of the cervix: histopathologic and clinical features. American Journal of Obstetrics and Gynecology 1977;129(3):304-15.
21. Ireland D, Hardiman P, Monaghan JM. Adenocarcinoma of the uterine cervix: a study of 73 cases. Obstetrics and Gynecology 1985;65(1):82-5.
22. Kilgore LC, Soong SJ, Gore H, Shingleton HM, Hatch KD, Partridge EE. Analysis of prognostic features in adenocarcinoma of the cervix. Gynecologic Oncology 1988;31(1):137-53.
23. Kjorstad KE. Adenocarcinoma of the uterine cervix. Gynecologic Oncology 1977;5(3):219-23.
24. Kleine W, Rau K, Schwoeorer D, Pfleiderer A. Prognosis of the adenocarcinoma of the cervix uteri: a comparative study. Gynecologic Oncology 1989;35(2):145-9.
25. Leminen A, Paavonen J, Forss M, Wahlström T, Vesterinen E. Adenocarcinoma of the uterine cervix. Cancer 1990;65:53-9.
26. Martel P, Connan L, Bonnet F, Delannes M, Farnarier J, Mihura J, et al. Adenocarcinomas of the uterine cervix: Diagnostic, prognostic and therapeutic aspects in a 49-case-control cohort. Journal de Gynecologie Obstetrique et Biologie de la Reproduction 2000;29(1):48-54.
27. Miller BE, Flax SD, Arheart K, Photopulos G. The presentation of adenocarcinoma of the uterine cervix. Cancer 1993;72(4):1281-5.
28. Milsom I, Friberg LG. Primary adenocarcinoma of the uterine cervix. A clinical study. Cancer 1983;52(5):942-7.
29. Morley GW, Seski JC. Radical pelvic surgery versus radiation therapy for stage I carcinoma of the cervix (exclusive of microinvasion). American Journal of Obstetrics and Gynecology 1976;126:785-98.
30. Newton M. Radical hysterectomy or radiotherapy for stage I cervical cancer. A prospective comparison with 5 and 10 years follow-up. American Journal of Obstetrics and Gynecology 1975;123:535-42.
31. Nola M, Tomiĉić I, Dotlić S, Morović A, Petroveĉki M, Jukić S. Adenocarcinoma of uterine cervix - prognostic significance of clinicopathologic parameters. Croatian Medical Journal 2005;46(3):397-403.
32. Papanikolaou A, Kalogiannidis I, Misailidou D, Goutzioulis M, Stamatopoulos P, Makedos A, et al. Results on the treatment of uterine cervix cancer: ten years experience. European Journal of Gynaecological Oncology 2006;27(6):607-10.
33. Perez CA, Grigsby PW, Camel HM, Galakatos AE, Mutch D, Lockett MA. Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update of a nonrandomized comparison. International Journal of Radiation Oncology, Biology, Physics 1995;31(4):703-16.
34. Piver MS, Marchetti DL, Patton T, Halpern J, Blumenson L, Driscoll DL. Radical hysterectomy and pelvic lymphadenectomy versus radiation therapy for small (less than or equal to 3 cm) stage IB cervical carcinoma. American Journal of Clinical Oncology 1988;11:21-4.
35. Rabin S, Browde S, Nissenbaum M, Koller AB, De Moor NG. Radiotherapy and surgery in the management of stage IB and IIA carcinoma of the cervix. South African Medical Journal 1984;65(10):374-7.
36. Roddick JW Jr, Greenelaw RH. Treatment of cervical cancer. A randomised study of operation and radiation. American Journal of Obstetrics and Gynecology 1971;109:754-64.
37. Rutledge FN, Galakatos AE, Wharton JT, Smith JP. Adenocarcinoma of the uterine cervix. American Journal of Obstetrics and Gynecology 1975;122(2):236-45.
38. Saigo PE, Cain JM, Kim WS, Gaynor JJ, Johnson K, Lewis JL. Prognostic factors in adenocarcinoma of the uterine cervix. Cancer 1986;57(8):1584-93.
39. Shingleton HM, Gore H, Bradley DH, Soong SJ. Adenocarcinoma of the cervix: I. clinical evaluation and pathologic features. American Journal of Obstetrics and Gynecology 1981;139(7):799-814.
40. Sundfor K, Trope CG, Kjorstad KE. Radical radiotherapy versus brachytherapy plus surgery in carcinoma of the cervix 2A and 2B long-term results from a randomized study 1968 to 1980. Acta Oncologica 1996;35 Suppl 8:99-107.
41. Townsend SL, Kurrle GR. Cancer of the cervix (stages 1B, 2A and 2B): treatment and results. Australian and New Zealand Journal of Obstetrics and Gynaecology 1980;20(4):224-7.
42. Waldenström A-C, Horvath G. Survival of patients with adenocarcinoma of the uterine cervix in western Sweden. International Journal of Gynecological Cancer 1999;9:18-23.
43. Wei M, Liang L, Yuan S. Adenocarcinoma of the uterine cervix: an analysis of 105 cases. Chinese Journal of Clinical Oncology 2005;32(21):1227-30.
44. Weiss RJ, Lucas WE. Adenocarcinoma of the uterine cervix. Cancer 1986;57(10):1996-2001.
45. Yamashita H, Nakagawa K, Tago M, Shiraishi K, Nakamura N, Ohtomo K, et al. Comparison between conventional surgery and radiotherapy for FIGO stage I-II cervical carcinoma: a retrospective Japanese study. Gynecologic Oncology 2005;97(3):834-9.
46. Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas, number 35, May 2002. Obstetrics and Gynecology 2002;99(5 Pt 1):855-67.
47. Alfsen GC, Thoresen SO, Kristensen GB, Skovlund E, Abeler VM. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990. Cancer 2000;89(6):1291-9.
48. Barter JF, Soong SJ, Shingleton HM, Hatch KD, Orr JW Jr. Complications of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer. Obstetrics and Gynecology 1989;32(3):292-6.
49. Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, et al. Carcinoma of the cervix uteri. Journal of Epidemiology and Biostatistics 2001;6:7-43.
50. Boronow RC, Rutledge FN. Vesicovaginal fistula, radiation and gynaecologic cancer. American Journal of Obstetrics and Gynecology 1971;111(1):85-90.
51. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. British Journal of Cancer 2003;89(5):834-9.
52. Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. Obstetrics and Gynecology 2003;102(4):765-73.
53. Chen RJ, Lin YH, Chen CA, Huang SC, Chow SN, Hsieh CY. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecologic Oncology 1999;73(2):184-90.
54. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ, 2001.
55. Drescher CW, Hopkins MP, Roberts JA. Comparison of the pattern of metastatic spread of squamous cell cancer and adenocarcinoma of the uterine cervix. Gynecologic Oncology 1989;33(3):340-3.
56. Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecologic Oncology 1995;59(1):38-44.
57. Farley J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No.5, version 2.0. Lyon: IARC Press, 2004.
58. Fletcher G. Textbook of Radiotherapy. 2nd Edition. Philadelphia: Lea & Febiger, 1973.
59. Georg P, Kirisits C, Goldner G, Dörr W, Hammer J, Pötzi R, et al. Correlation of dose-volume parameters, endoscopic and clinical rectal side effects in cervix cancer patients treated with definitive radiotherapy including MRI-based brachytherapy. Radiotherapy Oncology 2009;91(2):173-80.
60. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001;358(9284):781-6.
61. Green JA, Kirwan JJ, Tierney J, Vale CL, Symonds PR, Fresco LL, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD002225.pub2]
62. Grisaru D, Covens A, Chapman B, Shaw P, Colgan T, Murphy J, et al. Does histology influence prognosis in patients with early-stage cervical carcinoma?. Cancer 2001;92(12):2999-3004.
63. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
64. Hong JH, Tsai CS, Wang CC, Lai CH, Chen WC, Lee SP, et al. Comparison of clinical behaviours and responses to radiation between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas of the cervix. Changgeng Yi Xue Za Zhi/Changgeng Ji Nian Yi Yuan [Chang Gung Medical Journal/Chang Gung Memorial Hospital] 2000;23(7):396-404.
65. Ishikawa H, Nakanishi T, Inoue T, Kuzuya K. Prognostic factors of adenocarcinoma of the uterine cervix. Gynecologic Oncology 1999;73(1):42-6.
66. Kasamatsu T, Okada S, Tsuda H, Shiromizu K, Yamada T, Tsunematsu R, et al. Early invasive adenocarcinoma of the uterine cervix: criteria for nonradical surgical treatment. Gynecologic Oncology 2002;85(2):327-32.
67. Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S, Sasajima Y, et al. Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix. British Journal of Cancer 2009;100(9):1400-5.
68. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, III, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. New England Journal of Medicine 1999;340(15):1154-61.
69. Krane JF, Granter SR, Trask CE, Hogan CL, Lee KR. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer 2001;93(1):8-15.
70. Kucera H. Operation or irradiation of cervix carcinoma? [in German]. Gynakologisch-Geburtshilfliche Rundschau 1998;38(1):3-9.
71. Lai CH, Hsueh S, Hong JH, Chang TC, Tseng CJ, Chou HH, et al. Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery?. International Journal of Gynecological Cancer 1999;9(1):28-36.
72. Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, et al. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecologic Oncology 2002;84(1):115-9.
73. Liu S, Semenciw R, Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ: Canadian Medical Association Journal 2001;164(8):1151-2.
74. Look KY, Brunetto VL, Clarke-Pearson DL, Averette HE, Major FJ, Alvarez RD, et al. An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecologic Oncology 1996;63(3):304-11.
75. Maneo A, Colombo A, Mangioni NC, Landoni F. Randomised study between radical surgery and radiotherapy for the treatment of stage Ib-IIa cervical cancer. 20-year update. International Journal of Gynecological Cancer 2011;21 Suppl 3(12):s25.
76. Morris M. Early cervical carcinoma: are two treatments better than one?. Gynecologic Oncology 1994;54(1):1-3.
77. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. New England Journal of Medicine 1999;340(15):1137-43.
78. Nag S, Chao C, Erickson B, Fowler J, Gupta N, Martinez A, et al. The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. International Journal of Radiation Oncology, Biology, Physics 2002;52(1):33-48.
79. Nieminen P, Kallio M, Hakama M. The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstetrics and Gynecology 1995;85(6):1017-21.
80. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
81. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. International Journal Gynecology and Obstetrics 2009;105(2):107-8.
82. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Journal of Clinical Oncology 2000;18(8):1606-13.
83. Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstetrics and Gynecology 1974;44(2):265-72.
84. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
85. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New England Journal of Medicine 1999;340(15):1144-53.
86. Schoolland M, Allpress S, Sterrett GF. Adenocarcinoma of the cervix. Cancer 2002;96(1):5-13.
87. Small W Jr, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, et al. Consensus guidelines for the delineation of the clinical target volume for intensity modulated pelvic radiotherapy in the postoperative treatment of endometrial and cervical cancer. International Journal of Radiation Oncology, Biology, Physics 2008;71(2):428-34.
88. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States, a 24 year population-based study. Gynecologic Oncology 2000;78(2):97-105.
89. Taylor A, Rockall AG, Reznek RH, Powell MEB. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2005;63:1604-12.
90. Taylor A, Rockall AG, Powel MEB. An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition. Clinical Oncology 2007;19(7):542-50.
91. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. International Journal of Cancer 1998;75(4):536-45.
92. Waggoner SE. Cervical cancer. Lancet 2003;361(9376):2217-25.
93. Weiner S, Wizenberg MJ. Treatment of primary adenocarcinoma of the cervix. Cancer 1975;35(6):1514-16.
94. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. Journal of Clinical Oncology 1999;17(5):1339-48.